A Study of FT-4202 in Patients With Thalassemia or Sickle Cell Disease
Status:
Not yet recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of
etavopivat (FT-4202) in patients with thalassemia or sickle cell disease and test how well
etavopivat works to lower the number of red blood cell transfusions required and increase
hemoglobin.